Acute Pancreatitis Market worth $8.82 Billion by 2030 - Exclusive Report by The Insight Partners Pune, India, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Acute pancreatitis is a condition characterized by the inflammation of pancreas over a short period. It is a common disease and a leading cause of...

Navitas Initiates Strategic Manufacturing Investments TORRANCE, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry-leader in next-generation power semiconductors, announced the first in a series of strategic...

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI) MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May...

New CeCe Bear(R) Initiative to Provide Comfort and Financial Support to Children and Families Affected by Pediatric Epilepsy CeCe Cares Pediatric Epilepsy Foundation Kicks Off New Initiative at Leading Pediatric Epilepsy Centers Nationwide CHICAGO, Dec. 1, 2011 (GLOBE NEWSWIRE) -- CeCe Cares Pediatric Epilepsy...